Compare WSC & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSC | AMLX |
|---|---|---|
| Founded | 1944 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.8B |
| IPO Year | 2015 | 2021 |
| Metric | WSC | AMLX |
|---|---|---|
| Price | $16.42 | $26.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $25.20 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 3.2M | 1.3M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $2,281,446,000.00 | $380,786,000.00 |
| Revenue This Year | $2.69 | N/A |
| Revenue Next Year | $2.24 | $51,469.06 |
| P/E Ratio | $26.92 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $15.57 | $10.83 |
| 52 Week High | $29.77 | $41.14 |
| Indicator | WSC | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 36.42 | 38.73 |
| Support Level | $16.23 | $12.98 |
| Resistance Level | $18.73 | $29.30 |
| Average True Range (ATR) | 1.16 | 1.84 |
| MACD | -0.22 | -0.39 |
| Stochastic Oscillator | 2.85 | 7.71 |
WillScot Holdings Corp designs, delivers, and services on-site, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company include modular office complexes, mobile offices, classrooms, blast-resistant modules, clearspan structures, sanitation solutions, portable storage containers, and climate-controlled containers and trailers.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.